Kumari Priya, Pandav Kumud, Panwar Anuradha, Kukreti Shrikant, Nath Mala, Barthwal Ritu, Kumar Surat
Department of Chemistry, Dayalbagh Educational Institute, Dayalbagh, Agra, 282005, India.
Department of Biosciences and Bioengineering, Indian Institute of Technology, Roorkee, Uttarakhand, 247667, India.
J Comput Aided Mol Des. 2025 Jun 27;39(1):37. doi: 10.1007/s10822-025-00615-2.
Current research suggests that anthraquinone compounds have ability to interact with G4 DNA, leading to its stabilization and potential use as telomerase inhibitors in human cells. In light of this, a series of experiments to investigate the interaction between the compound 1,4-bis[(3-Piperidino)propanamido]anthracen-9,10-dione (1,4-BPAQ) and human telomeric DNA sequences in solutions rich in K and Na solutions was conducted. Employing various biophysical techniques and titration studies, it was observed that the binding of 1,4-BPAQ to G4 sequences resulted in notable changes in absorbance, including hypochromicity followed by hyperchromicity. Furthermore, extensive fluorescence quenching (94%) was accompanied by shifts in absorbance maxima, emission wavelength, and change in ellipticity (at 265 nm and 290 nm) was found in CD spectra. The data analysis indicated possible stoichiometries of 0.5:1 and 1:1 for the drug-quadruplex DNA complexes. Presence of a red shift suggested partial stacking between bases as primary interaction mode. Interestingly, binding affinity values were moderately higher in K-rich solution. In addition, a significant thermal stabilization effect of up to 25 °C in K environment, while no such stabilization was observed in Na solution upon ligand binding. Molecular docking studies revealed similar binding energies across all conformational variations, despite distinct contact patterns between the ligand and three different G4 DNA conformations (2HY9/2JPZ/143D). This research demonstrated the potential anticancer activity of 1,4-BPAQ through MTT assay, with apoptosis activity observed at lower concentrations (IC = 5.25 µM) against HepG2 cancer cells. These structural findings may hold significance in the context of drug development for anti-cancer therapies.
目前的研究表明,蒽醌化合物能够与G4 DNA相互作用,使其稳定,并有可能作为人类细胞中的端粒酶抑制剂。鉴于此,开展了一系列实验,以研究化合物1,4-双[(3-哌啶基)丙酰胺基]蒽-9,10-二酮(1,4-BPAQ)与富含钾和钠的溶液中的人类端粒DNA序列之间的相互作用。通过采用各种生物物理技术和滴定研究,观察到1,4-BPAQ与G4序列的结合导致吸光度发生显著变化,包括先减色后增色。此外,在CD光谱中发现,广泛的荧光猝灭(94%)伴随着最大吸收波长、发射波长的移动以及椭圆率的变化(在265nm和290nm处)。数据分析表明,药物-四链体DNA复合物的可能化学计量比为0.5:1和1:1。红移的存在表明碱基之间的部分堆积是主要的相互作用模式。有趣的是,在富含钾的溶液中结合亲和力值略高。此外,在钾环境中,配体结合后有高达25°C的显著热稳定作用,而在钠溶液中未观察到这种稳定作用。分子对接研究表明,尽管配体与三种不同的G4 DNA构象(2HY9/2JPZ/143D)之间的接触模式不同,但在所有构象变化中结合能相似。这项研究通过MTT试验证明了1,4-BPAQ的潜在抗癌活性,在较低浓度(IC = 5.25 µM)下对HepG2癌细胞观察到凋亡活性。这些结构发现可能在抗癌治疗药物开发方面具有重要意义。